Evaluation of the efficacy and safety of anisoylated plasminogen streptokinase activator complex in early myocardial infarction. Preliminary results

Drugs. 1987:33 Suppl 3:186-8. doi: 10.2165/00003495-198700333-00032.

Authors

S J Lenhoff¹, A R Horak, R C Fraser, R N Scott-Millar, A R Bird, P Jacobs, P J Commerford

Affiliation

¹ Department of Medicine, University of Cape Town, Groote Schuur Hospital.

PMID: 3315590
DOI: 10.2165/00003495-198700333-00032

No abstract available

MeSH terms

Anistreplase
Female
Fibrinolytic Agents / adverse effects
Fibrinolytic Agents / therapeutic use*
Hemostasis / drug effects
Humans
Male
Middle Aged
Myocardial Infarction / blood
Myocardial Infarction / drug therapy*
Plasminogen / adverse effects
Plasminogen / therapeutic use*
Streptokinase / adverse effects
Streptokinase / therapeutic use*

Substances

Fibrinolytic Agents
Anistreplase
Plasminogen
Streptokinase